Hunan Warrant Pharmaceutical Co. Ltd. A
Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products. It offers medicines in the areas of digestive, berating, anti-infection, gynecology, cardiovascular, cerebrovascular, immunology and nephrology, and other fields. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.
Hunan Warrant Pharmaceutical Co. Ltd. A (688799) - Total Liabilities
Latest total liabilities as of June 2025: CN¥667.46 Million CNY
Based on the latest financial reports, Hunan Warrant Pharmaceutical Co. Ltd. A (688799) has total liabilities worth CN¥667.46 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hunan Warrant Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Hunan Warrant Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hunan Warrant Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Hunan Warrant Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sichuan Guoguang Agrochemical Co Ltd
SHE:002749
|
China | CN¥325.29 Million |
|
DongHua Testing Technology Co Ltd
SHE:300354
|
China | CN¥105.22 Million |
|
Asseco Business Solutions S.A.
WAR:ABS
|
Poland | zł138.21 Million |
|
Yangtze Optical Fibre And Cable Joint Stock Limited Company
PINK:YZOFF
|
USA | $15.81 Billion |
|
Spartan Delta Corp
PINK:DALXF
|
USA | $479.95 Million |
|
Delfi Limited
PINK:PEFDF
|
USA | $175.28 Million |
|
Bohai Ferry Co Ltd
SHG:603167
|
China | CN¥508.26 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Hunan Warrant Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Warrant Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Warrant Pharmaceutical Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Hunan Warrant Pharmaceutical Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥637.06 Million | +55.87% |
| 2023-12-31 | CN¥408.70 Million | +16.66% |
| 2022-12-31 | CN¥350.35 Million | +10.15% |
| 2021-12-31 | CN¥318.07 Million | +23.25% |
| 2020-12-31 | CN¥258.07 Million | -13.48% |
| 2019-12-31 | CN¥298.27 Million | -- |